China-based office specialist’s IPO would be appealing if it is priced cheaply
Related Posts
Big Pharma, Bad Medicine, and What GSK Can Teach MNCs in China
ABB eyes emerging markets as it buys Power-One for US$1b
India defends solar panel makers from Chinese rivals
US bars Hong Kong consul from giving tough speech on protests
Morningside Venture Closes First RMB Fund At $140M Hard Cap
Olympic athletes complain of Covid quarantine conditions- Alibaba warns of slowdown in Chinese consumer spending
What the eclipse of Tencent by a liquor company says about Xi’s China
Twitter suspends hundreds of fake accounts spreading pro-China propaganda during the Olympics
Trade war inspires black humour on Chinese social media